-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
B cell maturation antigen (BCMA), as a target of multiple immunotherapy , is also a biomarker related to tumor burden in multiple myeloma (MM).
BCMA encoding gene TNFRSF17 is located on the short arm of chromosome 16, and it is almost exclusively expressed on plasma cells and B cells.
B cell maturation antigen (BCMA), as a target of multiple immunotherapy , is also a biomarker related to tumor burden in multiple myeloma (MM).
immunity
Previous studies have shown that the level of soluble sBCMA in the serum of MM patients is elevated and is related to the occurrence of the disease.
BCMA-related immunotherapies include CAR (Chimeric Antigen Receptor)-T cell therapy, which shows potential therapeutic activity in relapsed/refractory MM.
Although the reduction or loss of BCMA antigen expression has been observed in a small number of patients, the internal tumor mechanism of BCMA targeting CAR-T cell therapy has not yet been elucidated .
In this study, the researchers reported a MM patient with irreversible deletion of BCMA who participated in the KarMMa trial (NCT03361748).
The patient developed disease progression after receiving anti-BCMA CAR-T treatment.
Patient's clinical characteristics and BCMA expression
The researchers found that the homozygous deletion of the TNFRSF17 (BCMA) gene is a potential mechanism for immune escape.
In addition, further studies have shown that 37 out of 168 MM patients have a heterozygous deletion of TNFRSF17 or a partial deletion of chromosome 16.
Loss of heterozygosity for TNFRSF17 may be a major risk factor for loss of BCMA after immunotherapy.
org/10.
Leave a message here
